NCT04079712 2026-03-18Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting17 enrolled 12 charts
NCT04524208 2024-08-13CABONENUniversity Medical Center GoettingenPhase 2 Active not recruiting45 enrolled